



BHARATI VIDYAPEETH (DU) MEDICAL COLLEGE, PUNE

CRITERIA 3

LIST OF RESEARCH PROJECT

S r N o.	Name of Projects for the institute	Name of the Principal Investigat or/Co Investigat or	Name of the Funding agency	Departmen t of Principal Investigato r/ Co Investigato r	Year of Award	Duration of the project (months)
1	Baseline Assessment of Streptococcus pneumoniae in India Serotypes (BASIS)	Dr Sanjay Lalwani	INCLIN	Paediatrics	2015	26
2	Pneumonia Research Initiatives in rural areas and urban slums of Maharashtra	Dr J S Gothankar	Bill Melinda Gates Foundation through Inclean Trust International	Community Medicine	2015	24
3	MMRV Surveillance: Prevalence and Titres of Measles, Mumps, Rubella and Varicella Antibodies in Indian Infants and Toddlers: A Pilot Study	Dr Nandini Malshe	GSK Pharma India Pvt. Ltd.	Paediatrics	2016	20
4	Randomised double blind, Placebo Controlled, Phase 3 study to assess the safety and efficacy of ART-123 in subjects with severe sepsis and Cosguloopathy ART- 123	Dr Shivakumar Iyer	Asahi Kasei Pharma America Corporation	Critical Care Medicine	2016	24
5	PATH Rota 04: 'A Phase III, Multicenter, Open Label, Randomized Study of Bovine Rotavirus Pentavalent Vaccine (BRV-PV) To Evaluate Lot-To-Lot Consistency, And To Investigate Potential Interference With Routine UIP Vaccinations In Healthy Infants In India'.	Dr Sanjay Lalwani	Syngene/ SIIL	Paediatrics	2016	16

6	QIV 06 :‘Immunogenicity and Safety of a Single Dose or Two Doses Given 28 Days Apart of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Subjects Aged 6 Months or Older in India’	Dr Sanjay Lalwani	Sanofi Pasteur	Paediatrics	2016	10
7	Protocol 3-001: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Study to Assess the Safety, and Efficacy of ART-123 in subject with Severe Sepsis & Coagulopathy.	Dr. Shivakumar Iyer	ASIATIC CLINICAL RESEARCH PVT LTD	Critical Care Medicine	2016	24
8	MMRV Surveillance: Prevalence and Titres of Measles, Mumps, Rubella and Varicella Antibodies in Indian Infants and Toddlers: A Pilot Study	Dr Nandini Malshe	GSK Pharma India Pvt. Ltd.	Paediatrics	2016	20
9	Randomised double blind, Placebo Controlled, Phase 3 study to assess the safety and efficacy of ART-123 in subjects with severe sepsis and Cosgulopathy ART- 123	Dr Shivakumar Iyer	Asahi Kasei Pharma America Corporation	Critical Care Medicine	2016	24
10	QIV 06 :‘Immunogenicity and Safety of a Single Dose or Two Doses Given 28 Days Apart of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Subjects Aged 6 Months or Older in India’	Dr Sanjay Lalwani	Sanofi Pasteur	Paediatrics	2016	10
11	Randomised double blind, Placebo Controlled, Phase 3 study to assess the safety and efficacy of ART-123 in subjects with severe sepsis and Cosgulopathy ART- 123	Dr Shivakumar Iyer	Asahi Kasei Pharma America Corporation	Critical Care Medicine	2016	24
12	Rota 06 study: A Phase II/III, Multicentre, Open-Label, Randomized Study of Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-To-Lot Consistency and to Compare Non-Inferiority with ROTASIIL (Lyophilized BRV-PV) In Healthy Infants in India	Dr Sanjay Lalwani	Diagnosearch Life Sciences Pvt. Ltd.	Paediatrics	2017	12

1 3	Hepatitis A Phase I: An open label Phase I study to evaluate the Safety and Immunogenicity of HBI Inactivated Hepatitis-A Vaccine when administered as a single dose in two groups of healthy subjects of 19 to 49 years and 12 to 18 years of age.	Dr Sonali Palkar	Human Biologicals Institute	Paediatrics	2017	6
1 4	Rota 06 study: A Phase II/III, Multicentre, Open-Label, Randomized Study of Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-To-Lot Consistency and to Compare Non-Inferiority with ROTASIIL (Lyophilized BRV-PV) In Healthy Infants in India	Dr Sanjay Lalwani	Diagnosearch Life Sciences Pvt. Ltd.	Paediatrics	2017	12
1 5	Hepatitis A Phase I: An open label Phase I study to evaluate the Safety and Immunogenicity of HBI Inactivated Hepatitis-A Vaccine when administered as a single dose in two groups of healthy subjects of 19 to 49 years and 12 to 18 years of age.	Dr Sonali Palkar	Human Biologicals Institute	Paediatrics	2017	6
1 6	Cadila Pentavalent: A prospective, randomized, two-arm, single-blind, parallel, active-controlled, multicenter, non-inferiority clinical study to evaluate the immunogenicity and safety of Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) of M/s Cadila Healthcare Limited compared to Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) of M/s Panacea Biotec Limited in healthy infants.	Dr. Neeta Hanumante	Cadilla Health Care Ltd.	Paediatrics	2018	22

1 7	Shan 6-002 (Booster study): Safety and Immunogenicity of booster dose of a Hexavalent Vaccine SHAN6™ (DTwP-HepB-Hib-IPV) with or without co-administration of MMR vaccine in Toddlers.	Dr.Sonali Palkar	Shantha Biotec PVt Lts	Paediatrics	2018	20
1 8	Evaluation of Anti-hypertensive activity of NIF herbal grassroots leads	Dr.Pandit V.A	NIF-DST	Pharmacology	2018	48
1 9	Pre-clinical & clinical evaluation of anti-diabetic activity of NIF herbal leads	Dr.Pandit V.A	NIF-DST	Pharmacology	2018	48
2 0	Pre-clinical evaluation of Anti-Cataract activity of NIF grass root leads in immature cataract	Dr.Pandit V.A	NIF-DST	Pharmacology	2018	16
2 1	Serum Hexa Phase I- A Phase I, Prospective, Open Label Clinical Study to Assess the Safety and Immunogenicity of DTwP-HepB-IPV-Hib Vaccine Manufactured by SIIPL in Healthy Toddlers aged 16-24 Months	Dr Sanjay Lalwani	Serum Institute of India	Paediatrics	2018	8
2 2	Evaluation of Homocysteine, Folic Acid, Vitamin B12, MTHFR(C677T and A1298C) and ACE (I/D) gene polymorphisms as risk factors in young patients of Coronary Artery Disease	Dr.Rajni Shivkar	ICMR-STs project	Biochemistry	2018	48
2 3	Prevenar phase IV: A Phase 4, Randomized, Open-Label Trial to describe the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine formulated in Multidose Vials when given with routine Pediatric Vaccines in healthy infants in India	Dr Sanjay Lalwani	Pfizer/ ICON	Paediatrics	2018	30

2 4	Cadila Pentavalent: A prospective, randomized, two-arm, single-blind, parallel, active-controlled, multicenter, non-inferiority clinical study to evaluate the immunogenicity and safety of Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) of M/s Cadila Healthcare Limited compared to Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) of M/s Panacea Biotec Limited in healthy infants.	Dr. Neeta Hanumante	Cadilla Health Care Ltd.	Paediatrics	2018	22
2 5	Shan 6-002 (Booster study): Safety and Immunogenicity of booster dose of a Hexavalent Vaccine SHAN6™ (DTwP-HepB-Hib-IPV) with or without co-administration of MMR vaccine in Toddlers.	Dr Sonali Palkar	Shantha Biotec Pvt Lts	Paediatrics	2018	20
2 6	Serum Tdap- A phase II/III, multicenter, randomized, open label, active controlled, clinical study to assess the immunogenicity and safety of tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine manufactured by Serum Institute of India Pvt. Ltd. (SIPL) in comparison with Boostrix® vaccine of GSK in healthy adults, adolescents and children in India.	Dr Jitendra Oswal	JSS Medical Research India Private Ltd	Paediatrics	2018	37
2 7	Serum Hexa Phase I- A Phase I, Prospective, Open Label Clinical Study to Assess the Safety and Immunogenicity of DTwP-HepB-IPV-Hib Vaccine Manufactured by SIPL in Healthy Toddlers aged 16-24 Months	Dr Sanjay Lalwani	Serum Institute of India	Paediatrics	2018	8

28	<p>Protocol Title: A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil®) Protocol No: SII-qHPV/IN-02, Version 2.0 dated 24 April 2018 (126)</p>	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2018	48
29	<p>Prevenar phase IV: A Phase 4, Randomized, Open-Label Trial to describe the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine formulated in Multidose Vials when given with routine Pediatric Vaccines in healthy infants in India</p>	Dr Sanjay Lalwani	Pfizer/ ICON	Paediatrics	2018	30
30	<p>Cadila Pentavalent: A prospective, randomized, two-arm, single-blind, parallel, active-controlled, multicenter, non-inferiority clinical study to evaluate the immunogenicity and safety of Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) of M/s Cadila Healthcare Limited compared to Diphtheria, Tetanus, Pertussis (Whole Cell), Hepatitis B (rDNA) and Haemophilus influenzae Type b Conjugate Vaccine (Adsorbed) of M/s Panacea Biotec Limited in healthy infants.</p>	Dr. Neeta Hanumante	Cadilla Health Care Ltd.	Paediatrics	2018	22

3 1	Shan 6-002 (Booster study): Safety and Immunogenicity of booster dose of a Hexavalent Vaccine SHAN6™ (DTwP-HepB-Hib-IPV) with or without co-administration of MMR vaccine in Toddlers.	Dr Sonali Palkar	Shantha Biotec Pvt Lts	Paediatrics	2018	20
3 2	Serum Tdap- A phase II/III, multicenter, randomized, open label, active controlled, clinical study to assess the immunogenicity and safety of tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine manufactured by Serum Institute of India Pvt. Ltd. (SIPL) in comparison with Boostrix® vaccine of GSK in healthy adults, adolescents and children in India.	Dr Jitendra Oswal	JSS Medical Research India Private Ltd	Paediatrics	2018	37
3 3	Serum Hexa Phase I- A Phase I, Prospective, Open Label Clinical Study to Assess the Safety and Immunogenicity of DTwP-HepB-IPV-Hib Vaccine Manufactured by SIPL in Healthy Toddlers aged 16-24 Months	Dr Sanjay Lalwani	Serum Institute of India	Paediatrics	2018	8
3 4	Protocol Title: A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil®) Protocol No: SII-qHPV/IN-02, Version 2.0 dated 24 April 2018 (126)	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2018	48

3 5	Prevenar phase IV: A Phase 4, Randomized, Open-Label Trial to describe the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine formulated in Multidose Vials when given with routine Pediatric Vaccines in healthy infants in India	Dr Sanjay Lalwani	Pfizer/ ICON	Paediatrics	2018	30
3 6	Serum Tdap- A phase II/III, multicenter, randomized, open label, active controlled, clinical study to assess the immunogenicity and safety of tetanus toxoid, diphtheria toxoid, and acellular pertussis (Tdap) vaccine manufactured by Serum Institute of India Pvt. Ltd. (SIPL) in comparison with Boostrix® vaccine of GSK in healthy adults, adolescents and children in India.	Dr Jitendra Oswal	JSS Medical Research India Private Ltd	Paediatrics	2018	37
3 7	Protocol Title: A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil®) Protocol No: SII-qHPV/IN-02, Version 2.0 dated 24 April 2018 (126)	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2018	48
3 8	Prevenar phase IV: A Phase 4, Randomized, Open-Label Trial to describe the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine formulated in Multidose Vials when given with routine Pediatric Vaccines in healthy infants in India	Dr Sanjay Lalwani	Pfizer/ ICON	Paediatrics	2018	30

3 9	<p>Protocol Title: A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil®)</p> <p>Protocol No: SII-qHPV/IN-02, Version 2.0 dated 24 April 2018 (126)</p>	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2018	48
4 0	<p>Protocol Title: A Phase-II/III, Partially Double-blind, Randomized, Active-controlled, Multicentric Study to Assess the Immunogenicity and Safety of SIPL's qHPV Vaccine Administered Intramuscularly in Healthy Volunteers According to a Two-dose Schedule to Cohort 1 (Girls and Boys Aged 9-14 years) and a Three-dose Schedule to Cohort 2 (Women and Men Aged 15-26 years) as Compared to Merck's HPV6/11/16/18 vaccine (Gardasil®)</p> <p>Protocol No: SII-qHPV/IN-02, Version 2.0 dated 24 April 2018 (126)</p>	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2018	6
4 1	<p>A study of implementation of pre-conception care for preventing adverse pregnancy outcome in Nashik district, Maharashtra</p>	Dr. Prakash Doke	UNICEF	Community Medicine	2018	36

4 2	Peumosiil (PCV 10 003)- A Phase 3, Randomized, Double-Blind Study to Evaluate the Immunogenicity, Safety and Tolerability of Serum Institute of India's 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL®) in Healthy Indian Infants.	Dr Sanjay Lalwani	Serum Institute of India	Paediatrics	2019	22
4 3	SHAN 6 Phase III Immune Lot-to-Lot Consistency and Non-Inferiority of SHAN6™ vaccine in Comparison to SHAN 5® + SHANIPV™ When Administered as Three Doses at 6-8, 10-12 and 14-16 weeks of age in Healthy Indian Infants, Concomitantly with Oral Rotavirus Vaccine	Dr Sonali Palkar	Shantha Biotec Pvt Lts	Paediatrics	2019	22
4 4	Peumosiil (PCV 10 003)- A Phase 3, Randomized, Double-Blind Study to Evaluate the Immunogenicity, Safety and Tolerability of Serum Institute of India's 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL®) in Healthy Indian Infants.	Dr Sanjay Lalwani	Serum Institute of India	Paediatrics	2019	22
4 5	SHAN 6 Phase III Immune Lot-to-Lot Consistency and Non-Inferiority of SHAN6™ vaccine in Comparison to SHAN 5® + SHANIPV™ When Administered as Three Doses at 6-8, 10-12 and 14-16 weeks of age in Healthy Indian Infants, Concomitantly with Oral Rotavirus Vaccine	Dr Sonali Palkar	Shantha Biotec Pvt Lts	Paediatrics	2019	22
4 6	Hepatitis A study: A Phase II/III Multicentric Randomized Single Blind Study to Compare the Immunogenicity and Safety of HBI Inactivated Hepatitis-A Vaccine with Havrix® Vaccine when Administered to Two Age Groups of Healthy Subjects ”	Dr Sonali Palkar	Indian Immunological Limited	Paediatrics	2019	25

4 7	Birth Rota study : Protocol Title: A Phase 3, Multicenter, Open-Label, Randomized Clinical Trial To Evaluate Safety And Immunogenicity of ROTAVAC® -200C And ROTAVAC 5cm administered at Birth (Neonatal Schedule) and additional dose versus Infant Schedule against Rotavirus Gastroenteritis Protocol Number: BBIL/ROTAVAC/III/2018 Version 1.1 effective date 27 Oct 2018 (133)	Dr. Neeta Hanumante	CMS Clinical	Paediatrics	2019	8
4 8	PCV-10-004 study: A Phase 3, Randomized, Double-Blind Study to Evaluate the Immunogenicity, Safety and Tolerability of Serum Institute of India's 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL®) in Healthy Indian Infants.	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2019	21
4 9	Rotarix Liquid:A phase III, randomized, open study to assess the immunogenicity, reactogenicity and safety of two different formulations of GlaxosmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) vaccine, Rotarix, when given as a two dose Primary vaccination in healthy infants with no previous history of rotavirus illness or Vaccination.	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2019	20
5 0	Peumosiil (PCV 10 003)- A Phase 3, Randomized, Double-Blind Study to Evaluate the Immunogenicity, Safety and Tolerability of Serum Institute of India's 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL®) in Healthy Indian Infants.	Dr Sanjay Lalwani	Serum Institute of India	Paediatrics	2019	22

5 1	SHAN 6 Phase III Immune Lot-to-Lot Consistency and Non-Inferiority of SHAN6™ vaccine in Comparison to SHAN 5® + SHANIPV™ When Administered as Three Doses at 6-8, 10-12 and 14-16 weeks of age in Healthy Indian Infants, Concomitantly with Oral Rotavirus Vaccine	Dr Sonali Palkar	Shantha Biotec Pvt Lts	Paediatrics	2019	22
5 2	Hepatitis A study: A Phase II/III Multicentric Randomized Single Blind Study to Compare the Immunogenicity and Safety of HBI Inactivated Hepatitis-A Vaccine with Havrix® Vaccine when Administered to Two Age Groups of Healthy Subjects ”	Dr Sonali Palkar	Indian Immunological s Limited	Paediatrics	2019	25
5 3	Birth Rota study : Protocol Title: A Phase 3, Multicenter, Open-Label, Randomized Clinical Trial To Evaluate Safety And Immunogenicity of ROTAVAC® -200C And ROTAVAC 5cm administered at Birth (Neonatal Schedule) and additional dose versus Infant Schedule against Rotavirus Gastroenteritis Protocol Number: BBIL/ROTAVAC/III/2018 Version 1.1 effective date 27 Oct 2018 (133)	Dr. Neeta Hanumante	CMS Clinical	Paediatrics	2019	8
5 4	PCV-10-004 study: A Phase 3, Randomized, Double-Blind Study to Evaluate the Immunogenicity, Safety and Tolerability of Serum Institute of India's 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL®) in Healthy Indian Infants.	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2019	21
5 5	Rotarix Liquid:A phase III, randomized, open study to assess the immunogenicity, reactogenicity and safety of two different formulations of GlaxosmithKline (GSK) Biologicals' oral live attenuated	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2019	20

	human rotavirus (HRV) vaccine, Rotarix, when given as a two dose Primary vaccination in healthy infants with no previous history of rotavirus illness or Vaccination.					
5 6	Hepatitis A study: A Phase II/III Multicentric Randomized Single Blind Study to Compare the Immunogenicity and Safety of HBI Inactivated Hepatitis-A Vaccine with Havrix® Vaccine when Administered to Two Age Groups of Healthy Subjects ”	Dr Sonali Palkar	Indian Immunological s Limited	Paediatrics	2019	25
5 7	PCV-10-004 study: A Phase 3, Randomized, Double-Blind Study to Evaluate the Immunogenicity, Safety and Tolerability of Serum Institute of India’s 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL®) in Healthy Indian Infants.	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2019	21
5 8	Hepatitis A study: A Phase II/III Multicentric Randomized Single Blind Study to Compare the Immunogenicity and Safety of HBI Inactivated Hepatitis-A Vaccine with Havrix® Vaccine when Administered to Two Age Groups of Healthy Subjects ”	Dr Sonali Palkar	Indian Immunological s Limited	Paediatrics	2019	20
5 9	Cervical Cancer Knowledge and Human Papilloma Virus Vaccination Hesitancy in Adolescent Girls in Pune- A Quasi Experimental Study.	Anusha Mittal	ICMR-STs project	Community Medicine	2019	4
6 0	GSK Pertussis: Evaluation of Pertussis Disease in Young Infants in India - A Hospital Based Multi-centric study	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2020	12

6 1	Protocol Title: An open label, multicenter, randomized, controlled clinical trial to evaluate the efficacy and safety of Tablets of purified aqueous extract of <i>Cocculus hirsutus</i> in treatment of moderate COVID - 19 disease (AQCH) Protocol Version: 2.0, Dated 08/MAY/2020 (152)	Dr Shivakumar Iyer	Sun Pharmaceutical Industries Ltd.	Critical Care Medicine	2020	18
6 2	Hepatitis A Sero Prevalence study: Sero-prevalence of Anti-Hepatitis A antibodies in four cities from different parts of India	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2020	33
6 3	aPENTA vaccine Study:A Phase II/III, Multicentre, Randomized, Open-Label, Active-Controlled Study to Assess the Immunogenicity and Safety of DTaP-IPV+Hib Vaccine Manufactured by Serum Institute of India Pvt. Ltd. in Comparison with Pentaxim® in Indian Toddlers and Infants.	Dr. Jitendra Oswal	IQVIA RDS(India)Pvt Ltd	Paediatrics	2020	31
6 4	rBCG Study -A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Efficacy Of Recombinant BCG VPM1002 In Reducing Infection Incidence And Disease Severity Of SARS-COV-2/COVID-19 Among High-Risk Subjects	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2020	27
6 5	GSK Pertussis: Evaluation of Pertussis Disease in Young Infants in India - A Hospital Based Multi-centric study	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2020	12
6 6	Hepatitis A Sero Prevalence study: Sero-prevalence of Anti-Hepatitis A antibodies in four cities from different parts of India	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2020	33

6 7	A Phase 1, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety And Tolerability Of Ceftazidime-Avibactam (Caz-Avi) In Children From 3 Months To Less Than 18 Years Of Age Who Are Hospitalized And Receiving Systemic Antibiotic Therapy For Suspected Or Confirmed Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia	Dr Vijay Kalrao	Syneos Health UK Ltd	Paediatrics	2020	11
6 8	Edoxaban for IntraCranial Hemorrhage survivors with Atrial Fibrillation- ENRICH-AF	Dr. (Brig) Sankar Parsad Gorthi	Hamilton Health Sciences Corporation (HHSC)	Neurology	2020	12
6 9	A Phase 2 evaluation of the efficacy of homoeopathic remedy Zincum muriaticum as an adjuvant therapy to standard of care in adult subjects with moderate to severe COVID-19: Randomized, double-blind, parallel group, placebo controlled, multicenter trial (ZIMCOV).	Dr.Prachee Makashir	Homoeocon Foundation Pune	General Medicine	2020	12
7 0	SH600004 ; SHAN 6 Phase III- Phase III, randomized, open-label, multicenter study evaluating the immunogenicity and safety of Shan6 vaccine administered, concomitantly with or without Measles-Mumps Rubella (MMR) vaccine, to healthy toddlers in India.	Dr Sonali Palkar	Sanofi Healthcare Ltd	Paediatrics	2020	12
7 1	HBI MR vaccine study: A Phase II/III Multicentric Randomized Single Blind Study to Compare the Immunogenicity and Safety of Measles and Rubella Vaccine (Live) of HBI with MR-VAC® Vaccine in Healthy Subjects	Dr. Rahul Jahagirdar	Human Biologicals Institute	Paediatrics	2020	13
7 2	ICMR COVISHIELD vaccine study: A Phase 2/3 Observer-Blind, Randomized, Controlled Study To Determine The Safety and Immunogenicity of COVISHIELD (Covid-19 Vaccine) In Healthy Indian Adults	Dr Sanjay Lalwani	SIPL in collaboration with ICMR	Paediatrics	2020	13

7 3	aPENTA vaccine Study: A Phase II/III, Multicentre, Randomized, Open-Label, Active-Controlled Study to Assess the Immunogenicity and Safety of DTaP-IPV+Hib Vaccine Manufactured by Serum Institute of India Pvt. Ltd. in Comparison with Pentaxim® in Indian Toddlers and Infants.	Dr. Jitendra Oswal	IQVIA RDS(India)Pvt Ltd	Paediatrics	2020	31
7 4	rBCG Study -A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Efficacy Of Recombinant BCG VPM1002 In Reducing Infection Incidence And Disease Severity Of SARS-COV-2/COVID-19 Among High-Risk Subjects	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2020	27
7 5	GSK Pertussis: Evaluation of Pertussis Disease in Young Infants in India - A Hospital Based Multi-centric study	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2020	12
7 6	Hepatitis A Sero Prevalence study: Sero-prevalence of Anti-Hepatitis A antibodies in four cities from different parts of India	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2020	33
7 7	Anti- coronavirus therapies (ACT) to prevent progression of COVID 19 trial	Dr. Purwa Doke	Hamilton Health Sciences through its Population Health Research Institute. Hamilton, Canada	General Medicine	2020	1
7 8	A Phase 2 evaluation of the efficacy of homoeopathic remedy Zincum muriaticum as an adjuvant therapy to standard of care in adult subjects with moderate to severe COVID-19: Randomized, double-blind, parallel group, placebo controlled, multicenter trial (ZIMCOV).	Dr.Prachee Makashir	Homoeocon Foundation Pune	General Medicine	2020	12

7 9	SH600004 ; SHAN 6 Phase III-Phase III, randomized, open-label, multicenter study evaluating the immunogenicity and safety of Shan6 vaccine administered, concomitantly with or without Measles-Mumps Rubella (MMR) vaccine, to healthy toddlers in India.	Dr Sonali Palkar	Sanofi Healthcare Ltd	Paediatrics	2020	12
8 0	HBI MR vaccine study: A Phase II/III Multicentric Randomized Single Blind Study to Compare the Immunogenicity and Safety of Measles and Rubella Vaccine (Live) of HBI with MR-VAC® Vaccine in Healthy Subjects	Dr. Rahul Jahagirdar	Human Biologicals Institute	Paediatrics	2020	13
8 1	ICMR COVISHIELD vaccine study: A Phase 2/3 Observer-Blind, Randomized, Controlled Study To Determine The Safety and Immunogenicity of COVISHIELD (Covid-19 Vaccine) In Healthy Indian Adults	Dr Sanjay Lalwani	SI IPL in collaboration with ICMR	Paediatrics	2020	13
8 2	aPENTA vaccine Study:A Phase II/III, Multicentre, Randomized, Open-Label, Active-Controlled Study to Assess the Immunogenicity and Safety of DTaP-IPV+Hib Vaccine Manufactured by Serum Institute of India Pvt. Ltd. in Comparison with Pentaxim® in Indian Toddlers and Infants.	Dr. Jitendra Oswal	IQVIA RDS(India)Pvt Ltd	Paediatrics	2020	31
8 3	rBCG Study -A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study To Evaluate The Efficacy Of Recombinant BCG VPM1002 In Reducing Infection Incidence And Disease Severity Of SARS-COV-2/COVID-19 Among High-Risk Subjects	Dr Sanjay Lalwani	DiagnoSearch Life Sciences Pvt. Ltd.	Paediatrics	2020	36
8 4	GSK Pertussis: Evaluation of Pertussis Disease in Young Infants in India - A Hospital Based Multi-centric study	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2020	26

85	Anti- coronavirus therapies (ACT) to prevent progression of COVID 19 trial	Dr. Purwa Doke	Hamilton Health Sciences through its Population Health Research Institute. Hamilton, Canada	General Medicine	2020	24
86	A Phase 2 evaluation of the efficacy of homoeopathic remedy Zincum muriaticum as an adjuvant therapy to standard of care in adult subjects with moderate to severe COVID-19: Randomized, double-blind, parallel group, placebo controlled, multicenter trial (ZIMCOV).	Dr.Prache Makashir	Homoeocon Foundation Pune	General Medicine	2020	22
87	SH600004 ; SHAN 6 Phase III-Phase III, randomized, open-label, multicentre study evaluating the immunogenicity and safety of Shan6 vaccine administered, concomitantly with or without Measles-Mumps Rubella (MMR) vaccine, to healthy toddlers in India.	Dr Sonali Palkar	Sanofi Healthcare Ltd	Paediatrics	2020	37
88	HBI MR vaccine study: A Phase II/III Multicentre Randomized Single Blind Study to Compare the Immunogenicity and Safety of Measles and Rubella Vaccine (Live) of HBI with MR-VAC® Vaccine in Healthy Subjects	Dr. Rahul Jahagirdar	Human Biologicals Institute	Paediatrics	2020	48
89	aPENTA vaccine Study:A Phase II/III, Multicentre, Randomized, Open-Label, Active-Controlled Study to Assess the Immunogenicity and Safety of DTaP-IPV+Hib Vaccine Manufactured by Serum Institute of India Pvt. Ltd. in Comparison with Pentaxim® in Indian Toddlers and Infants.	Dr. Jitendra Oswal	IQVIA RDS(India)Pvt Ltd	Paediatrics	2020	24
90	Assessment of Gender Wise Awareness and Attitude Regarding Menstruation and Menstrual Hygiene Management.	Abhipsa Sinha	ICMR	Community Medicine	2020	12

9 1	Protocol Title: An international randomized trial of additional treatments for COVID-19 in hospitalized patients who are all receiving the local standard of care (Solidarity Trial) Protocol Version & Date: 10.0 dated 22 Mar 2020	Dr. Jignesh Shah	ICMR	Critical Care Medicine	2020	12
9 2	Assessment of reasons of vaccine hesitancy in slum dwellers in Pune	Sidhant Damle	ICMR	Community Medicine	2020	2
9 3	A Phase I Randomized Single Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of Chikungunya Vaccine (Inactivated) of HBI when administered by two different dosage schedules to Healthy Subjects of 19 To 49 Years of Age.	Dr Sonali Palkar	Human Biologicals Institute	Paediatrics	2021	14
9 4	Behavioral and biological risk factors of non communicable diseases among adults in urban slums of Pune using STEPS Approach.	Dr Sudhanshu Mahajan	BVU Funded	Community Medicine	2021	12
9 5	Birth Rota vaccine extended study: To Evaluate the Long-term Persistence of Rotavirus Antibody Responses in Children Previously Vaccinated With a 3-Dose Infant Schedule or 4-Dose Neonatal Schedule with ROTAVAC® -20°C or ROTAVAC 5D®	Dr. Neeta Hanumante	Bharat Biotech	Paediatrics	2021	13
9 6	A Phase I Randomized Single Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of Chikungunya Vaccine (Inactivated) of HBI when administered by two different dosage schedules to Healthy Subjects of 19 To 49 Years of Age.	Dr Sonali Palkar	Human Biologicals Institute	Paediatrics	2021	14

9 7	Covovax Pediatric Vaccine: A phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults aged ≥18 years and children aged 2 to 17 years.	Dr Sanjay Lalwani	SIILP/PPD	Paediatrics	2021	15
9 8	Parenting stress in Health Care Workers from tertiary level Covid-19 care hospitals in India during the pandemic and its associated factors: a two-centre cross-sectional survey	Dr Vijay Kalrao	BVU Funded	Paediatrics	2021	12
9 9	Birth Rota vaccine extended study: To Evaluate the Long-term Persistence of Rotavirus Antibody Responses in Children Previously Vaccinated With a 3-Dose Infant Schedule or 4-Dose Neonatal Schedule with ROTAVAC® -20°C or ROTAVAC 5D®	Dr. Neeta Hanumante	Bharat Biotech	Paediatrics	2021	13
1 0 0	Genova Covid 19 Vaccine- A Prospective, Multicentre, Randomized, Active-controlled, Observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects	Dr Sonali Palkar	Gennova Biopharmaceuticals Limited	Paediatrics	2021	19
1 0 1	Co-relates of COVID 19 vaccine hesitancy/ acceptance among adult population: A Community based study	Dr Sanjivani Patil	BVU funded	Community Medicine	2021	12

1 0 2	A phase III, randomized, multi-center, double-blind, placebo-controlled, study to evaluate the efficacy, safety, and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited. Protocol No: NCOV.20.002, Version 03 Dated 08 Jan 2021	Dr Sanjay Lalwani	Zyodus Cadilla study	Paediatrics	2021	16
1 0 3	A Phase I Randomized Single Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of Chikungunya Vaccine (Inactivated) of HBI when administered by two different dosage schedules to Healthy Subjects of 19 To 49 Years of Age.	Dr Sonali Palkar	Human Biologicals Institute	Paediatrics	2021	10
1 0 4	Covovax Pediatric Vaccine: A phase 2/3, observer-blind, randomized, controlled study to determine the safety and immunogenicity of COVOVAX [SARS-CoV-2 recombinant spike protein nanoparticle vaccine (SARS-CoV-2 rS) with Matrix-M1™ adjuvant] in Indian adults aged ≥18 years and children aged 2 to 17 years.	Dr Sanjay Lalwani	SIILP/PPD	Paediatrics	2021	20
1 0 5	Parenting stress in Health Care Workers from tertiary level Covid-19 care hospitals in India during the pandemic and its associated factors: a two-centre cross-sectional survey	Dr Vijay Kalrao	BVU Funded	Paediatrics	2021	22
1 0 6	Genova Covid 19 Vaccine- A Prospective, Multicentre, Randomized, Active-controlled, Observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate the Safety, Tolerability and Immunogenicity of the candidate HGCO19 (COVID-19 vaccine) in healthy subjects	Dr Sonali Palkar	Gennova Biopharmaceuticals Limited	Paediatrics	2021	25

107	Community Behavior Change Communication (CBCC) for improving childhood immunization coverage among children in urban slums and brickkilns in rural area	Dr Sujata Murarkar	BVU Funded	Community Medicine	2021	36
108	GSK RSVMAT-012:A Phase III, double-blind, randomized, placebo-controlled study to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV Maternal vaccine, in high risk pregnant women aged 15 to 49 years and infants born to the vaccinated mothers.	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2021	4
109	Local Production of WHO recommended hand rub formulation and comparison of its efficacy with a commercially available alcohol based hand rub.	Ms.SHAGUN	ICMR	Microbiology	2021	12
110	Verification of sub National claims for TB free status in India, 2020	Dr J S Gothankar	ICMR	Community Medicine	2021	1
111	Death Audit of Registered Tuberculosis Patients in Pune Municipal Corporation Area	Dr. Prakash Doke	RNTCP, Govt. of Maharashtra	Community Medicine	2021	8
112	Prevalence of HLA B* 1502(SNP rs144012689) and HLA A* 3101 alleles in Indian patients treated with Anti-Epileptic Dugs and its correlation with Severe Cutaneous Adverse Reaction (AED-SCAR study).	Dr. Kavita Srivastava	ICMR	Paediatrics	2021	12
113	Prevalence of low birth weight and its association with maternal factors in tertiary care centre in Pune	Rajnandini Kulkarni	ICMR	Community Medicine	2021	2
114	Protocol Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa Trial Code: MET55 (137)	Dr Sonali Palkar	IQVIA RDS(India)Pvt Ltd	Paediatrics	2022	36

1 1 5	Protocol Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa Trial Code: MET55 (137)	Dr Sonali Palkar	IQVIA RDS(India)Pvt Ltd	Paediatrics	2022	36
1 1 6	Protocol Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa Trial Code: MET55 (137)	Dr Sonali Palkar	IQVIA RDS(India)Pvt Ltd	Paediatrics	2022	36
1 1 7	Protocol Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa Trial Code: MET55 (137)	Dr Sonali Palkar	IQVIA RDS(India)Pvt Ltd	Paediatrics	2022	36
1 1 8	GSK Augmentin: A Multicentre, Open-label, Non-comparative Phase IV Clinical Study to Evaluate the Safety and Clinical Efficacy of Augmentin Extra Strength (ES)-600 (amoxicillin/potassium clavulanate 14:1 combination) in Children with Acute Respiratory Tract Infections (ARTIs) in India.	Dr. Neeta Hanumante	GSK Pharma India Pvt. Ltd.	Paediatrics	2022	11

1 1 9	Lung Cancer- A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevaciz-umab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC).	Dr. Shreeniwas Raut	Clinsearch Healthcare Solutions Pvt. Ltd, Thane (W), Mumbai.	Oncology	2022	24
1 2 0	BBIL CHIKV: A Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age.	Dr Sonali Palkar	Bharat Biotech	Paediatrics	2022	24
1 2 1	Can IgG specific column agglutination cards replace Dithiothreitol (DTT)	Dr. BRINDA KAKKAR	BVU Funded	Immunohe matology	2022	4
1 2 2	PERFORMANCE EVALUATION OF RPR AND ELISA WITH TPHA FOR DETECTION OF SYPHILIS IN BLOOD DONORS	Dr. BRINDA KAKKAR	BVU Funded	Immunohe matology	2022	4
1 2 3	Protocol Title: Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa Trial Code: MET55 (137)	Dr Sonali Palkar	IQVIA RDS(India)Pvt Ltd	Paediatrics	2022	12
1 2 4	Diagnostic Potential of Intestinal permeability markers in irritable bowel syndrome	Dr Gayatri Gawade	BVU funded ,CRPU Funded in collaboration with Gastroenterology, Medicine Dept,BVDTU MC,Pune-43	Biochemistr y	2022	24

1 2 5	Cadila TCV MR: A prospective, randomized, parallel, three-arm, open-label, multicenter, phase IV clinical trial to evaluate the immunological non-interference of Typhoid Vi conjugate vaccine with Measles and Rubella vaccine administered to healthy infants	Dr. Neeta Hanumante	Cadilla Health Care Ltd.	Paediatrics	2022	8
1 2 6	GSK Augmentin: A Multicentre, Open-label, Non-comparative Phase IV Clinical Study to Evaluate the Safety and Clinical Efficacy of Augmentin Extra Strength (ES)-600 (amoxicillin/potassium clavulanate 14:1 combination) in Children with Acute Respiratory Tract Infections (ARTIs) in India.	Dr. Neeta Hanumante	GSK Pharma India Pvt. Ltd.	Paediatrics	2022	22
1 2 7	Lung Cancer- A Multicenter, Randomised, Double blind, Parallel, Phase III Global Study to Assess the Efficacy and Safety of BP01 (Bevacizumab) when compared to Avastin®-EU in Combination with Carboplatin and Paclitaxel during Induction phase and Bevaciz-umab alone during the Maintenance phase in patients with newly diagnosed or recurrent Stage IIIB/IV Non Squamous (ns) Non-Small Cell Lung Cancer (NSCLC).	Dr. Shreeniwas Raut	Clinsearch Healthcare Solutions Pvt. Ltd, Thane (W), Mumbai.	Oncology	2022	12
1 2 8	BBIL CHIKV: A Seamless Phase II/III, Observer-blind, Multi-centre, Randomized Clinical Trial to Evaluate Immunogenicity and Safety of BBV87, an Inactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65 Years of Age.	Dr Sonali Palkar	Bharat Biotech	Paediatrics	2022	12
1 2 9	Reliance Growth Hormone: A prospective, multi-centre, phase IV study to evaluate safety and efficacy of SomatoRel™ (recombinant human growth hormone manufactured by Reliance Life Sciences Pvt. Ltd.) in growth hormone deficient children	Dr. Rahul Jahagirdar	Reliance Life Sciences Pvt. Ltd.	Paediatrics	2022	21

1 3 0	Serum Covovax Booser: A phase 3, observer-blind, randomized, controlled study to evaluate the safety and immunogenicity of a booster dose of COVOVAX in Indian adults who have received primary vaccination against COVID-19	Dr Sanjay Lalwani	PPD Pharmaceutical Development India Pvt Ltd	Paediatrics	2022	27
1 3 1	Synergistic activity of ceftazidime-avibactam plus aztreonam against carbapenemase producing enterobacteriaceae and its clinical implications	Dr. Aishwarya Babu	BVU Funded	Microbiology	2022	12
1 3 2	Training program for Medical Officers of public health system as master trainers on prevention and management of Chronic Obstructive Pulmonary Disease and Asthma based on government guidelines	Dr. Medha Bhargaje	Cipla	Pulmonary medicine	2022	33
1 3 3	RSV MAT 009: A Phase III, randomized, double-blind, placebo-controlled study to demonstrate efficacy of a single dose of unadjuvanted RSV Maternal vaccine, administered IM to pregnant women 18 to 49 years of age, for prevention of RSV associated LRTI in their infants up to 6 months of age	Dr Sanjay Lalwani	GSK Pharma India Pvt. Ltd.	Paediatrics	2022	12

1 3 4	RCC- Protocol Title: A Multicentric, Open-label, Randomized, Two Period, Two Treatment, Two Sequence, Crossover, Multiple Dose, Steady state Bioequivalence Study of Pazopanib tablets 200 mg of Eugia Pharma Specialities Limited, India (Test) with VOTRIENT® (pazopanib) tablets 200 mg of Novartis Pharmaceuticals Corporation, USA (Reference) in adult patients with advanced renal cell carcinoma already receiving Pazopanib HCl tablets in standard therapy, and who are tolerating a stable dosing regimen of 800 mg/day (4 × 200 mg) under fasting conditions. Protocol number: CR200-18 Protocol Version & Date: Version 1.0, Amendment-02, Dated 20.01.2022	Dr. Shreeniwas Raut	Raptim	Oncology	2022	12
1 3 5	Healthcare Access for Rural Community via Telemedicine	Dr. Varsha Vaidya	BVU Funded	Community Medicine	2022	8
1 3 6	Evaluation of antifertility potential of entada rheedii spreng seed kernel extract in female wistar rats	Dr. Jayshree Dawane	BVU Funded	Pharmacology	2022	1
1 3 7	Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, and Children in India and Healthy Adolescents and Children in the Republic of South Africa	Dr Sonali Palkar	Sanofi Pasteur	Pharmacology	2022	15

1 3 8	HBI Dengue: A PHASE I SINGLE BLIND RANDOMIZED PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF LIVE ATTENUATED TETRAVALENT RECOMBINANT DENGUE VACCINE OF HBI IN HEALTHY ADULTS OF 18 TO 50 YEARS OF AGE	Dr Sonali Palkar	Abiogenesis Clinpharm Pvt Ltd	Paediatrics	2022	14
1 3 9	Assessment of micronutrient status of phase II MBBS Students:Prospective dietary Interventional study	Miss Ashalesha Kulkarni	BVU Funded	Biochemistry	2022	24
1 4 0	Preventive and Therapeutic Potential of Swarna Bhasma and Jasad Bhasma in Diabetic Retinopathy and Diabetic Nephropathy',	Dr.Pallawi Khatavkar	ICMR	Pharmacology	2022	12
1 4 1	Sarcopenia , Obesity and Sarcopenic obesity in patients with Type II DM and established cardiovascular disease: A Pilot study of prevalence and association	Mr Amanpreet Singh Wasir	ICMR-STS project	Physiology	2022	4
1 4 2	Evaluation of musculoskeletal disorders in IT professionals	Mr Atharv Pande	ICMR-STS project	Physiology	2022	4
1 4 3	Prevalence of APOA5 and CD36 gene polymorphisms in lipid metabolizing genes in patients with Type 2 diabetes mellitus - A pilot study	Anu Chiristopher	BVU Funded	Pathology	2023	8
1 4 4	Prospective, Randomized, Multi-centric, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of KSM-66 Ashwagandha (Withania somnifera) in Adults Experiencing High Stress and/or Anxiety	Dr. Priti Pravin Dhande	External funded	Pharmacology	2023	48
1 4 5	ASSESSMENT OF THE PREVALENCE OF PSYCHOLOGICAL AND SPIRITUAL HEALTH IN CANCER CHEMOTHERAPY PATIENS.	Dr. Shilpa Patankar	BVU Funded	Surgery	2023	1

1 4 6	Experimental evaluation of antianxiety and antidepressant effect of Ashwagandha Root extract in wistar rats	Dr. Jayshree Dawane	Clinsearch Healthcare Solutions Pvt. Ltd, Thane (W), Mumbai.	Pharmacology	2023	12
-------------	---	---------------------	--	--------------	------	----